A Clinical Picture of the Visual Outcome in Adamantiades-Behçet's Disease.

Michele Figus, Chiara Posarelli, Timothy G Albert, Rosaria Talarico, Marco Nardi

Open access · hybridAbstract readReview

In one paragraph

Review in BioMed research international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

0.3field-weighted citation impact, top 37% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Michele FigusDepartment of Surgical, Medical, Molecular Pathology and Department of Emergency, University of Pisa, 56100 Pisa, Italy.

Chiara PosarelliDepartment of Surgical, Medical, Molecular Pathology and Department of Emergency, University of Pisa, 56100 Pisa, Italy.

Timothy G AlbertDepartment of Surgical, Medical, Molecular Pathology and Department of Emergency, University of Pisa, 56100 Pisa, Italy.

Rosaria TalaricoRheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, 56100 Pisa, Italy.

Marco NardiDepartment of Surgical, Medical, Molecular Pathology and Department of Emergency, University of Pisa, 56100 Pisa, Italy.

University of Pisa · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adamantiades-Behçet's disease is a multisystemic vasculitis with multiorgan involvement. Ocular disorders occur often in this syndrome typically in the form of a relapsing-remitting panuveitis and vasculitis and can lead to blindness as one of its most disabling complications if left untreated. There are known risk factors related with the worst visual prognosis, which require early and intensive treatment in order to obtain a rapid suppression of inflammation and to prevent future relapses. The management strategy to avoid vision loss and blindness currently involves the use of local and systemic drugs including steroids and immunosuppressive and biologic agents. This review aims to demonstrate how the introduction and the use of biologic agents improves the visual outcome of patients with Adamantiades-Behçet's disease.

Indexed as

Behcet SyndromeBiological FactorsBlindnessHumansImmunosuppressive AgentsPrognosisVisual AcuityBiological FactorsImmunosuppressive Agents

Identifiers

PMID26558256

DOI10.1155/2015/120519

PMCPMC4628956

OpenAlexW2103421367

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.